Dyadic International (NASDAQ:DYAI) Shares Cross Below 50-Day Moving Average – Here’s Why

Dyadic International Inc. (NASDAQ:DYAI)’s stock price passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $0.79 and traded as low as $0.6870. Dyadic International shares last traded at $0.7106, with a volume of 79,647 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $3.00.

Dyadic International Stock Performance

The stock’s 50 day moving average price is $0.79 and its 200 day moving average price is $0.85. The company has a current ratio of 2.42, a quick ratio of 2.42 and a debt-to-equity ratio of 4.08. The company has a market cap of $25.89 million, a price-to-earnings ratio of -3.09 and a beta of 1.17.

Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. The company had revenue of $1.11 million for the quarter, compared to analyst estimates of $0.90 million. On average, analysts expect that Dyadic International Inc. will post 0.13 EPS for the current fiscal year.

Institutional Trading of Dyadic International

A number of institutional investors and hedge funds have recently bought and sold shares of DYAI. Apis Capital Advisors LLC acquired a new stake in Dyadic International during the 3rd quarter worth approximately $1,817,000. Landscape Capital Management L.L.C. acquired a new position in shares of Dyadic International during the third quarter worth about $190,000. Truist Financial Corp lifted its stake in shares of Dyadic International by 30.5% during the third quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock worth $385,000 after purchasing an additional 76,200 shares in the last quarter. Marathon Capital Management lifted its stake in shares of Dyadic International by 142.9% during the fourth quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 50,000 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 36,266 shares in the last quarter. Institutional investors and hedge funds own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.